Samsung Bioepis has submitted a biosimilar version of Roche's breast cancer blockbuster Herceptin in the EU, hard on the heels of rivals Biocon and Mylan.

Vietnam has been one of the fastest-growing economies in Asia in recent years, and Sanofi has just cut a deal to give it a stronger position in the market.

Government warns drugmakers could leave the UK if the country's separation from the EU drags on and is kept under wraps.

Abbott picked up Vietnamese drug manufacturer Glomed for an undisclosed price in a deal that gives the pharma giant two manufacturing facilities in that…

Another Indian API maker is in trouble over manufacturing issues. This time it is an Artemis Biotech plant in Hyderabad and it is the German drug authority…

Zhejiang Hisun will handle greater China efforts on GEN-1 from Celsion in an expanded partnership aimed at costs and faster approvals.

Samsung BioLogics is reported to be ready to file an IPO application this week in South Korea that is seen raising more than $2 billion.

Pfizer executives spent considerable time on the second-quarter earnings call discussing biosimilar plans related to China and South Korea's Celltrion.

Gilead Sciences has confirmed a report that several Indian drugmakers have licenses to manufacture its cutting-edge hepatitis treatment Epclusa.